In a previously completed global Phase 2 clinical trial in patients with Relapsing-Remitting MS (RRMS), orelabrutinib ... s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback